|
|
| Line 1: |
Line 1: |
| {| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
| | |
| ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ticagrelor|{{fontcolor|#6C7B8B|Ticagrelor}}]]'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | BRILINTA<sup>®</sup> FDA Package Insert
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor indications and usage|Indications and Usage]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor dosage and administration|Dosage and Administration]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor dosage forms and strengths|Dosage Forms and Strengths]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor contraindications|Contraindications]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor warnings and precautions|Warnings and Precautions]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor adverse reactions|Adverse Reactions]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor drug interactions|Drug Interactions]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor use in specific populations|Use in Specific Populations]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor overdosage|Overdosage]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor description|Description]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor clinical pharmacology|Clinical Pharmacology]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor nonclinical toxicology|Nonclinical Toxicology]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor clinical studies|Clinical Studies]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor how supplied storage and handling|How Supplied/Storage and Handling]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor patient counseling information|Patient Counseling Information]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ticagrelor labels and packages|Labels and Packages]]
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Ticagrelor
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
| |
| |-
| |
| |}
| |